Indications |
Oral Gastro-oesophageal reflux disease Adult: For erosive oesophagitis: 20 mg once daily in the morning for 4-8 wk. Maintenance: 10-20 mg once daily according to response. For non-erosive oesophagitis: 10 mg once daily for 4 wk, upon symptom resolution, may continue with 10 mg once daily when necessary. Oral Hypersecretory conditions Adult: Initially, 60 mg daily adjusted according to response. Max dose: 120 mg daily. Oral Active peptic ulcer disease Adult: 20 mg daily given for 4-8 wk for duodenal ulcer and 6-12 wk for gastric ulcer. Oral H.pylori infection Adult: As a combination with two antibacterials: 20 mg bid combined with clarithromycin 500 mg bid and either amoxicillin 1 g bid or metronidazole 400 mg bid. To be taken for a wk. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Severe hepatic impairment, gastric malignancy. May increase the risk of GI infections due to acid suppressive effects. Pregnancy. |
Adverse Reactions |
Headache, diarrhoea, rash, infection and flu-like syndrome. Dizziness, fatigue, constipation, nausea and vomiting. Potentially Fatal: Anaphylaxis, agranulocytosis. |
Overdose Reactions |
May result in drowsiness, headache and tachycardia. |
Drug Interactions |
May reduce absorption of ketoconazole and itraconazole. May prolong the elimination of diazepam, phenytoin and warfarin. See Below for More rabeprazole Drug Interactions |
Food Interactions |
Delayed absorption with high-fat meals. |
Mechanism of Actions |
Rabeprazole is a PPI that suppresses gastric acid secretion by inhibiting the gastric H+/K+ ATPase at the secretory surface of the gastric parietal cell. Onset: 1 hr. Duration: 24 hr. Absorption: Oral bioavailability: about 52% and peak plasma concentrations are reached about 3.5 hr after oral admin. Distribution: Protein-binding: 97%. Metabolism: Extensively metabolised in the liver by cytochrome P450 isoenzymes. Excretion: Metabolites are mainly excreted in the urine (90%). Half-life: about 1 hr. |
Administration |
Delayed-release: May be taken with or without food. |
Storage Conditions |
Oral: Store at 15-30°C. |
ATC Classification |
A02BC04 - rabeprazole ; Belongs to the class of proton pump inhibitors. Used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD). |
Storage |
Oral: Store at 15-30°C. |
Available As |
|
Rabeprazole
Post Review about Rabeprazole Click here to cancel reply.
Rabeprazole Containing Brands
Rabeprazole is used in following diseases
Drug - Drug Interactions of Rabeprazole
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.